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Potential and future strategies for radiotherapy in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) continues to be one of the
worst cancer conditions worldwide, being the sixth most
common cancer and associated with a 5-year overall survival
rate of only 5% (1). Surgery, either in terms of local resection or
liver transplant, is still the treatment of choice, with 5-year
survival rates of 30–70% (2). However, o20% of patients
qualify for this treatment because of intrahepatic cancer multi-
focality, extrahepatic tumour manifestations, inadequate liver
function and/or involvement of vascular or biliary structures.
Alternative local treatment options for localized HCC include
radiofrequency ablation (RFA), percutaneous ethanol injection
(PEI), radiotherapy and transarterial chemoembolization
(TACE). Two randomized trials have shown that TACE leads
to an improved survival compared with best supportive care
(3, 4), but its efﬁcacy is modest and restricted to patients
without portal vein thrombosis.
The use of radiotherapy for locoregional treatment of HCC
has long been studied. The relatively low tolerance of the whole
liver to radiotherapy traditionally prohibited the application of
sufﬁciently high doses to control local tumour growth, leading
to a general notion of HCC as a ‘radioresistant condition’.
However, radiotherapy underwent major technological
improvements during the last decades including diagnostic
imaging, radiotherapy planning techniques [three-dimensional
(3D) conformal radiotherapy, intensity-modulated radiother-
apy and stereotactic body radiosurgery], image-guided radio-
therapy to detect to the exact position of the tumour at the time
of treatment along with respiration-gated radiotherapy to
account for liver movements because of breathing. Moreover,
radiotherapy with highly conformal protons and carbon ions is
increasingly available. All these technological advances allow to
treat liver tumours much more precisely, thereby minimizing
dose to uninvolved liver tissue and other organs at risk. Because
of the opening of the therapeutic window, radiotherapy has
lately gained increased consideration for treatment of HCC,
speciﬁcally in cases of failures to standard treatments [recently
reviewed in (5)].
In this issue of Liver International, Seong et al. (6) report on
the practice patterns and outcome in 398 radiation-treated
HCC patients in Korea. Data from 10 Korean institutions were
collected. The vast majority of patients have been treated by
3D-conformal radiotherapy after failure of TACE. The paper
conﬁrms the results of a previous report of the authors on
a subset of patients from one single institution, where multi-
variate analysis revealed increased radiation dose to be an inde-
pendent prognostic factor for improved overall survival (7).
This is also in line with the results of the University of Michigan
group, having shown that dose-escalated radiotherapy above
75Gy is associated with increased overall survival in patients
with liver malignancies (8).
In the current paper by Seong et al., overall survival was also
found to beassociated with absenceof lymph node involvement
and smaller tumour size, the latter being most probably linked
to a better local control rate. However, because of the retro-
spective nature of the current study, no systematic data were
available to estimate response rates. In a French prospective
phase II trial with 66Gy given to either single HCCs Z5cm
or two HCCs  3cm, a response rate of 92% has been
achieved, the complete response rate being 80% (9). At a
median follow-up of 29 months, the in-ﬁeld local control rate
was 78%, indicating the high potential of local tumour cure
by radiotherapy.
It is well established that the risk of liver toxicity in radio-
therapy-treated patients is both dependent on radiotherapy-
related parameters such as dose per irradiated liver volume as
well as on host factors including the extent of liver cirrhosis. In
the French prospective trial, Child–Pugh class A patients had
considerably less liver toxicities (25% grade 3, 0% grade 4) than
Child–Pugh class B patients (45% grade 3, 27% grade 4).
However, although 3D-conformal radiotherapy planning is
widely used, enabling to study partial volumen liver tolerance,
systematic data on the interdependence of dose to liver volume,
host factors and liver radiotherapy toxicity are scarce. It is
strongly recommended to prospectively include such analyses
in future radiotherapy trials.
For a long time, systemic chemotherapeutic approaches in
HCC have had limited success, with low response rates.
Recently, sorafenib – an oral multikinase inhibitor – has been
tested successfully in a prospective randomized trial in
advancedHCC (10). Given the high rate of incidenceof tumour
relapses outside the irradiated volumen as well as the radio-
sensitizing properties of many targeted agents, there is a
strong rationale to explore their combination with future high-
precision radiotherapy approaches.
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